Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

New compounds under development at AstraZeneca for treatment of thrombosis

Aug. 7, 2000

Boehringer Ingelheim claims new antithrombotic compounds

Aug. 4, 2000

Dalteparin reduces risk of clotting after hip replacement surgery

Aug. 4, 2000

New Roche compounds inhibit amidolytic activity of factor VIIa/tissue factor complex

Aug. 1, 2000

TxA2 antagonism and antiplatelet effects of new torasemide derivative BM-531

July 28, 2000

Rapid thrombolysis without reocclusion following acute bolus administration of novel modified t-PA

July 24, 2000

AstraZeneca describes new P2T receptor antagonists useful as antithrombotics

July 21, 2000

Innohep approved by FDA for DVT

July 20, 2000

FDA clears ConjuChem to initiate phase I/II trial of thrombin inhibitor

July 18, 2000

Berlex presents newly synthesized series of anticoagulants

July 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....